Metabolic dysfunction-associated steatohepatitis

This study looks at whether the diabetes drug pioglitazone can improve how the liver processes energy in people with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Researchers will measure liver mitochondrial function using special tracers before and after 16 weeks…

This Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…

This study looks at how the liver responds to food and a drug called semaglutide in people with non-alcoholic fatty liver disease (NAFLD). About 84 adults, including healthy volunteers, will take part. Researchers will check if semaglutide can reduce liver fat and damage over 30 …

This phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…

This Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …

This study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…

This study tests a new medicine called BI 3802876 in adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as an infusion, and ar…

This Phase 3 study tests an experimental drug called pegozafermin in 762 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. Participants receive weekly injections of the drug or a placebo for about two years. The goal is to see if the drug can improve l…

This Phase 3 trial tests whether efimosfermin alfa can improve liver fibrosis in adults with compensated cirrhosis caused by MASH (a fatty liver disease). Participants receive either the drug or a placebo via injection. The main goal is to see if liver scarring improves by at lea…

This phase 3 study tests whether an experimental drug called efimosfermin alfa can prevent serious liver complications in adults with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). Participants receive either the drug or a placebo as a shot …

This study tests a new drug, pegozafermin, in 1,350 adults with MASH (a type of fatty liver disease) and moderate liver scarring (stage F2 or F3). The goal is to see if the drug can improve scarring or resolve liver inflammation without making the disease worse over 52 weeks. Par…

This early-stage trial is testing an experimental drug called INI-822 to see if it is safe and tolerable. It involves healthy volunteers and people with MASH, a type of fatty liver disease. The study will give different doses of the drug or a placebo to see how the body handles i…

This early-stage study tests a new drug called OPK-88006 in 30 people, first in healthy volunteers and then in those with MASH (a serious liver condition). The goal is to check safety, how the drug moves through the body, and early signs of liver improvement. Results will help de…

This trial compares two approaches for treating advanced metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. About 120 adults with MASH and liver fibrosis will be randomly assigned to either metabolic surgery (gastric bypass or sl…

This study tests whether resmetirom, a daily pill, can reduce liver fat in people who have had a liver transplant and developed MASH (a type of fatty liver disease). About 120 participants will be randomly assigned to receive either resmetirom or a placebo for 28 weeks. The main …

This Phase 3 trial tests whether efimosfermin alfa can improve liver scarring and reduce inflammation in people with MASH (a type of fatty liver disease). About 1,200 adults with moderate-to-severe liver fibrosis will receive the drug or a placebo for 52 weeks. The goal is to see…

This phase 3 trial tests a drug called efimosfermin alfa in 1250 adults with MASH (a fatty liver disease) and moderate liver scarring. The main goal is to check safety and side effects. Participants will receive either the drug or a placebo, and researchers will monitor liver hea…

This phase 3 trial tests efruxifermin, a weekly injection, in 2,150 adults with liver scarring (cirrhosis) caused by NASH/MASH, a type of fatty liver disease. Half get the drug, half get a placebo. The goal is to see if efruxifermin can prevent serious liver events like liver fai…

This Phase 2 trial tests a drug called ALN-HSD, which uses gene silencing to target liver scarring in people with MASH, a fatty liver disease that can lead to cirrhosis. The study enrolls 120 adults with genetic risk factors and moderate-to-severe liver fibrosis. Researchers will…

This phase 2 trial tests a drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) caused by fatty liver disease (MASH). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to check safety and how the drug moves through …

This study tests an experimental drug called ALN-CIDEB in adults with fatty liver conditions (MASLD or MASH). The main goal is to check safety and tolerability, and also to see if the drug can reduce liver fat. About 132 participants will receive either the drug or a placebo. Thi…

This study tests whether taking a low dose of niacin (vitamin B3) after meals can help reduce fat stored in the liver for people with metabolic fatty liver disease (MASLD). Researchers will compare niacin to a placebo in 36 adults aged 50 to 80. The goal is to see if niacin can r…

This study tests whether a minimally invasive procedure called endoscopic sleeve gastroplasty (ESG), which reduces stomach size by 70%, can help reverse fatty liver disease (MASH) in people with obesity. Researchers will compare ESG plus lifestyle changes to lifestyle changes alo…

This study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting therapies, can improve liver health in people who have both MASH (a severe fatty liver disease) and type 2 diabetes. About 300 adults will receive either the drug combo or a p…

This study compares two approaches for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity. Half of the 48 participants will receive vertical sleeve gastrectomy surgery along with lifestyle counseling, while the other half will get lifestyle…

This study tests whether a low dose of digoxin, a drug normally used for heart problems, can help people with a severe type of fatty liver disease called NASH (also known as MASH). The trial will involve 144 adults with biopsy-confirmed NASH and liver scarring. Participants will …

This study tests an investigational drug called TGM-312-SC01, given as a shot, for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition. It first checks safety and drug levels in healthy adults, then in people with MASH. The trial is currently recrui…

This study tests a new drug called HU6 for people with MASH, a serious fatty liver disease. About 180 adults aged 30 and older will receive either HU6 or a placebo to see if the drug safely reduces liver fat. The trial lasts 26 weeks and focuses on safety and how well the drug wo…

This study tests if weight-loss surgery is better than standard medical treatment for making nonalcoholic steatohepatitis (NASH) with advanced liver scarring disappear without making the scarring worse. It involves 100 obese adults with NASH and significant liver fibrosis. Partic…

This early-stage trial tests an experimental drug called NNC0581-0001 in 48 adults with fatty liver and suspected liver inflammation. Participants receive three monthly injections of either the drug or a placebo. The main goal is to check safety and how the drug moves through the…

This study tests whether a daily injection of tesamorelin can safely reduce liver fat in adults with metabolic fatty liver disease (MASLD). About 120 participants will receive either the drug or a placebo for 52 weeks, along with lifestyle advice. The main goal is to measure chan…

This study tests a new tablet called CS060380 for adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. About 120 participants will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track a…

This study tests whether a low dose of the thyroid hormone Synthroid can help treat nonalcoholic steatohepatitis (NASH), a serious liver condition common in Veterans. About 128 overweight or obese Veterans with NASH will take either Synthroid or a placebo daily for one year. The …

This study tests resmiterom, the first FDA-approved drug for MASH (a type of fatty liver disease), in 165 Pakistani patients. Researchers will check how safe it is and whether it improves liver health using non-invasive scans. The goal is to see if the drug works well in this spe…

This Phase 3 trial tests whether hydroxychloroquine, a drug used for malaria and autoimmune diseases, can improve nonalcoholic steatohepatitis (NASH), a type of fatty liver with inflammation. 210 adults with confirmed fatty liver and elevated liver enzymes will take either 200 mg…

This study tests a new medicine, IBI362, in 165 adults with MASH, a serious fatty liver disease that can lead to scarring. Participants will receive either a low dose, high dose, or a placebo for 60 weeks. The main goal is to see if the drug can improve liver health without makin…

This study tests a new drug called UBT251, given as a weekly injection, for people with MASH (a serious fatty liver disease with scarring). 156 adults will be randomly assigned to receive one of three doses of UBT251 or a placebo for 48 weeks. The main goal is to see if the drug …

This study tests if a tube-like device called a stent, placed through a scope, can reverse gastric bypass surgery in 20 people who have serious complications like low blood sugar, blockages, or liver problems. The goal is to see if the stent works as well as surgery to fix these …

This study tests a drug called ADI-PEG 20 against a placebo in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive injections over 24 weeks, and doctors measure changes in liver fat using MRI. The goal is to see if the drug can …

This study is testing a new, non-invasive liver scan called iLivTouch to see if it can accurately detect a serious liver condition called MASH in people who have both type 2 diabetes and fatty liver disease. The scan measures liver inflammation, fat, and stiffness without any nee…

This study is collecting blood samples from 575 adults with fatty liver disease to find new, noninvasive tests that can detect liver scarring (fibrosis). Currently, doctors rely on a painful liver biopsy to check for scarring, but this research aims to replace that with a simple …

This study is testing a new, non-invasive MRI scan (called cT1) to see if it can accurately diagnose NASH, a serious liver disease. Currently, doctors need to take a small sample of liver tissue with a needle (biopsy) to confirm the diagnosis. The study will compare the MRI resul…

This study is looking at whether a blood test called the Enhanced Liver Fibrosis (ELF) test can find early signs of fatty liver disease in people who are at high risk, such as those with diabetes, high blood pressure, or heart disease. Researchers will review medical records of 3…

This study tests whether a special ultrasound done during an endoscopy can accurately detect liver scarring in people with obesity and suspected non-alcoholic fatty liver disease. Researchers will compare this new method to standard tests and liver biopsy in 150 adults. The proce…

This study is testing whether measuring spleen stiffness with a special ultrasound probe can detect advanced liver scarring in people with metabolic fatty liver disease (MASLD). Researchers will follow 500 adults for up to several years to see if the test predicts serious liver p…

This study is testing whether combining new blood tests and stool analysis can detect liver fibrosis earlier than current methods. Researchers will follow 1200 adults referred to a community liver clinic. The goal is to identify advanced liver disease sooner and reduce unnecessar…

This pilot study is testing a new Thermoacoustic Enhanced Ultrasound device to measure fat in the liver. Researchers will compare the device's readings to the gold-standard MRI measurement in 49 adults with fatty liver disease. The goal is to develop a more accessible and afforda…

This study is testing a new way to measure liver scarring using an endoscopic ultrasound with special software. About 300 adults with suspected liver disease will undergo this new scan, a standard liver biopsy, and another non-invasive test. The goal is to see if the new techniqu…

This study is testing whether a time-restricted eating plan (eating only during an 8-10 hour window each day) combined with a healthy plant-based diet is safe and doable for people with liver cancer, cirrhosis, or fatty liver disease. Fifty overweight or obese adults will either …

This study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…

This trial asks whether fructose, a sugar found in fruit and processed foods, causes more liver inflammation in people with MASH (a serious fatty liver disease) than in those with milder fatty liver or no liver disease. Over four weeks, participants follow a low-sugar diet and th…

This study follows 250 people newly diagnosed with HIV and 161 healthy volunteers over five years to see who develops metabolic fatty liver disease (MASLD). Researchers use annual blood tests, ultrasounds, and FibroScans to measure liver fat and stiffness. The goal is to uncover …

This 10-year observational study follows 20,000 Chinese adults with non-alcoholic fatty liver disease (NAFLD) or its more severe form, NASH. Researchers aim to measure how common these conditions are and how they progress over time. By collecting medical data and blood samples, t…

This study follows children aged 1 to 18 with biopsy-confirmed nonalcoholic fatty liver disease (NAFLD) to track how the condition changes over time. Researchers will monitor for liver-related death, cirrhosis complications, and the need for liver transplants. The goal is to bett…

This study creates a large database and biobank of people with nonalcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver. Researchers will collect medical data and biological samples over time to study how the disease develops, progresses, and respond…

This study looks at whether certain gene variations in the donor and the recipient influence how much fat builds up in the new liver after a living-donor transplant for MASH-related cirrhosis. Researchers will compare genetically related and unrelated donor-recipient pairs to sep…

This early-stage trial is testing a new drug called BI 3804379 in healthy adults to see if it is safe and how the body processes it. About 106 healthy men and women aged 18 to 65 will receive either the drug or a placebo as a shot under the skin. The study focuses on side effects…

This study looks at how gut bacteria produce certain chemicals that might worsen fatty liver disease (MASLD). Researchers will collect stool, blood, and urine samples from 24 people with the condition and healthy volunteers. They aim to identify which bacteria are responsible for…

This study uses a device called FibroScan to measure liver stiffness and fat content in people with liver disease. The scan is non-invasive, like an ultrasound, and takes only a few minutes. Researchers aim to build a large database of these measurements to help improve future di…

This early-phase study tests a new way to use PET scans to measure inflammation in both the liver and brain at the same time. Researchers will scan 12 adults with fatty liver disease using two different tracers (18F-FDG and 18F-DPA-714) to see if the new method can reliably detec…

This study looks at whether new MRI techniques can spot NASH, the serious form of fatty liver disease, without needing a liver biopsy. Researchers will scan 110 adults who already need a biopsy to see if the MRI can match the biopsy results. If successful, it could lead to a safe…

This early-stage study tests a single dose of an experimental drug called efimosfermin alfa in 32 adults with fatty liver disease and varying degrees of liver damage. The goal is to see how the drug moves through the body and whether it is safe. Participants must have liver cirrh…

This study will screen 2,000 people with HIV for fatty liver disease using a painless ultrasound technique. The goal is to catch liver problems early and improve long-term care. Researchers will also track how different HIV medications affect liver health.

This study will follow 20,000 elderly people with fatty liver disease to learn what factors affect their health. Researchers will look at lifestyle, genetics, and environment to understand how the disease progresses. The goal is to create better risk assessment tools and preventi…

This early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…

This study is not testing a new drug or treatment. Instead, researchers want to make sure their lab tests and equipment give accurate and repeatable results when studying conditions like obesity, diabetes, heart disease, and bone loss. Up to 100 healthy volunteers and people with…

This early-stage study tests an experimental drug called HEC169584 in 96 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it, not to treat any disease. Results will help guide future studies for non-alcoholic steatohepatitis (…

This study tracks the safety of the liver drug Rezdiffra (resmetirom) in women with NASH who take it while pregnant or breastfeeding. Researchers will follow about 10 women and their infants up to 12 months old to check for birth defects, growth problems, and other health issues.…

This study is recruiting 710 adults with fatty liver disease or alcohol-related liver disease, with or without cirrhosis, to understand why some develop liver cancer. Researchers will analyze genetic markers, immune factors, and imaging data from routine liver biopsies and blood …

This study looks at how androgens (a type of sex hormone) might affect fatty liver disease in young women. Researchers will compare changes in liver fat and stiffness over time in 150 women with and without PCOS. The goal is to understand the connection, not to test a treatment.

This study follows 240 adults with NASH-related cirrhosis to find better ways to detect early signs of liver failure, such as internal bleeding, fluid buildup, or confusion. Researchers will track health records and exams over time to improve monitoring. The goal is to understand…

This study looks at the gut bacteria of 3000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria linked to each disease to better understand how the gut and liver interact. This is an observational study, not a …

This study is re-examining 1,400 adults in Stockholm to find early signs and risk factors for heart, lung, and liver diseases. Participants will get advanced scans, blood tests, and questionnaires. The goal is to better understand how these diseases develop and how to predict the…

This study looks at the genes in colon polyps from people with MASH (a type of fatty liver disease) compared to those without fatty liver. Researchers want to find specific gene patterns that might signal higher risk. About 100 adults already scheduled for polyp removal will dona…

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This study from Mayo Clinic looks at how inflammation in fat tissue may affect the liver in people with severe obesity. Researchers will measure liver stiffness and fat tissue markers in 60 adults before they have weight-loss surgery. The goal is to better understand why some peo…

This early-stage study tests a new drug called ECC4703, being developed for a serious fatty liver condition (MASH). Researchers want to see how taking the drug with or without food changes the amount that gets into the blood. 72 healthy adults will receive a single dose of the dr…

This study looks at how common non-alcoholic fatty liver disease (NAFLD) and its more serious form, NASH, are in Olmsted County, Minnesota. Researchers will follow 800 adults over time to better diagnose these conditions and see how they affect long-term health, including risks f…

This study looks at how tiny communication points inside liver cells (called MAMs) change in people with a fatty liver disease called MASH. Researchers will collect liver and blood samples from 20 adults having weight-loss surgery. The goal is to understand what goes wrong in the…

This study collects blood and urine samples from 500 people with alcoholic liver disease, heavy drinkers without liver disease, and healthy non-drinkers. The goal is to create a biorepository that researchers can use to study biomarkers and improve understanding of the disease. P…

This study looks at how certain genes increase the risk of liver cancer (hepatocellular carcinoma) in people with nonalcoholic fatty liver disease (NAFLD). Researchers will follow 500 adults aged 45-75 with NAFLD to understand how genetic factors and lifestyle interact. The goal …

This study uses tiny, lab-grown liver models (organoids) made from patient cells to understand how a specific gene variant (I148M of PNPLA3) contributes to non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. Researchers will expose these mini-livers to fatty acid…

This is the first time BAR502, an experimental drug for NASH (a serious liver condition), is being tested in humans. The study involves 52 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive either a single dose or multiple…

This study interviews 25 people with MASH (a fatty liver disease linked to metabolism) to learn about their expectations, attitudes, and unmet needs before and after joining a special heart-liver program. Participants will have two private interviews. The goal is to improve care …

This study looks at the immune cells inside the liver of people with non-alcoholic fatty liver disease (NAFLD). The goal is to find differences between those with simple fatty liver and those with the more serious form, NASH, which can lead to cirrhosis and liver cancer. Research…